Map of Pancreatica Walks and Runs

Category Archives: Pancreatic Cancer Clinical Trials

Results in on Double Punch Vaccine: Why the FDA Granted Orphan Status to CRS-207 + GVAX in Pancreatic Cancer this Past Fall

A quick note related to an earlier Pancreatica blog posting from October 24, 2013. At the 2014 Gastrointestinal Cancers Symposium in San Francisco (January 16-18) as hosted by the American Society of Clinical Oncology (ASCO), the results of an interesting vaccine study for pancreatic cancer were released. By way of background in the fall 2013, […]

Share Button

Tarceva Plus Gemcitabine After Surgery for Cancer of the Pancreas?

Gress and colleagues from the University of Marburg in Germany published the results of a Phase II trial in the October issue of the Annals of Oncology, the official journal of the European Society for Medical Oncology. They did a prospective multi-center study of 76 patients over a two-year period which offered the adjuvant regimen […]

Share Button

FDA Grants Orphan Status for CRS-207 (Mesothelin Targeting Vaccine) in Sequence with GVAX Immunotherapy

In an interesting step with intriguingly complex promise, the Office of Orphan Products Development of the U.S. Food and Drug Administration recently designated the immunotherapy CRS-207 as having orphan drug status for use in sequential combination with the GVAX Pancreas biologic for the treatment of pancreatic cancer. Both of these immunotherapeutic agents are owned by […]

Share Button
Page 2 of 41234